Navigation Links
Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
Date:2/19/2013

on, as a result of the inclusion of legacy Actavis results.

For the full year 2012, Actavis Pharma net revenue increased 32 percent to $4.45 billion, including product sales of $4.39 billion and other revenue of $61.0 million, primarily due to higher international revenues as a result of the acquisitions of Ascent and the Actavis Group in January 2012 and November 2012, respectively, as well as full year sales of the authorized generic versions of Concerta® and Lipitor® in the U.S., launched in May 2011 and November 2011, respectively. 

Actavis Pharma's adjusted gross margin increased from 46.2 percent in 2011 to 46.6 percent in 2012.Actavis Specialty Brands Segment InformationThree Months EndedTwelve Months EndedDecember 31,December 31, (Unaudited; $ in millions)2012201120122011Product sales

$
2.6$
.1$
411.6$
364.9Other revenue

19.620.870.876.1Net revenue

132.2120.9482.4441.0Operating expenses:Cost of sales

30.626.1115.494.4Research and development

30.76.9146.267.7Selling and marketing

45.346.5175.5168.6Segment contribution

$
25.6$
41.4$
45.3$
.3Segment margin

19.4%34.2%9.4%25.0%Adjusted gross profit (1)

$
.6$
94.8$
367.0$
347.2Adjusted gross margin

76.9%78.4%76.1%78.7%(1)Adjusted gross profit represents net revenue less

adjusted cost of sales and excludes amortization of

acquired intangibles. Pro forma adjustments for the

respective periods include the following: Acquisition and licensing

$
-$
-$
-$
.6Actavis Specialty Brands net revenue increased 9 percent to $132.2 million in the fourth quarter. The increase was due to higher sales of key promoted products including Generess® Fe and Rapaflo® and the addition of Kadian®, which was acquired with the acquisition
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. Aethlon Medical Note: Fiscal Year Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: ... Office (USPTO) has issued a key patent covering ... vaccine targeting six tumor antigens that are commonly ... No. 8,871,211, which issued October 28, 2014, include ... dendritic cell composition comprising peptide epitopes of the ...
(Date:12/15/2014)... December 15, 2014 ... 19. und 20. Februar sind alle akkreditierten ... MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, ... geben, die neue profitablen Unternehmensdienstleistungen, die für ...
(Date:12/15/2014)... December 15, 2014 BerGenBio AS, ... aggressive drug resistant cancers, today announces that it has ... placing from new and existing investors. BerGenBio ... the development of its pipeline of innovative cancer therapeutics, ... lead drug candidate, BGB324, a first-in-class selective Axl kinase ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2BerGenBio Completes NOK90 Million Fundraising 2
... DIEGO, March 10, 2011 Orexigen® Therapeutics, Inc. (Nasdaq: ... today announced financial results for the three months and year ended ... 31, 2010 For the three months ended December ... $0.24 per share, as compared to a net loss of $15.0 ...
... 2011 Dendreon Corporation (Nasdaq: DNDN ) ... (FDA) approved the remainder of its New Jersey manufacturing ... of PROVENGE® (sipuleucel-T) to help meet the needs of ... (hormone refractory) prostate cancer.   Last April, ...
Cached Medicine Technology:Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results 2Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results 3Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results 4Dendreon Expands Launch of PROVENGE 2Dendreon Expands Launch of PROVENGE 3Dendreon Expands Launch of PROVENGE 4Dendreon Expands Launch of PROVENGE 5
(Date:12/19/2014)... December 19, 2014 Slone ... diagnostic, personalized medicine, healthcare information technology, and laboratory ... position of Chief Operating Officer. The announcement comes ... marked by a strengthened presence in Boston and ... "Leslie lives and breathes the client experience," said ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- Being in good ... researchers report. They looked at data from more than ... who underwent treadmill tests between 1991 and 2009. Those ... chance of having high blood pressure at the start of ... with high levels of fitness. Of the more than ...
(Date:12/19/2014)... -- Traveling through the same U.S. airport gate, one ... within a four-hour time span, illustrating just how easily ... "The exposures in this report were not prolonged and ... highlighting the fact that measles is highly contagious," wrote ... specialist at the U.S. Centers for Disease Control and ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Unidesk ... Osteopathic Medicine (ACOM), which welcomed its inaugural class ... Infrastructure (VDI) to seamlessly support bring your own ... and teaching – experience. The solution, comprised of ... , Dell server and storage infrastructure ...
(Date:12/17/2014)... Miami, FL (PRWEB) December 17, 2014 ... has not been able to eradicate the head louse ... and hassle for parents. Each year between six and ... Lice Troopers, the Miami-based lice removal treatment company comes ... safe, non-toxic and environmentally friendly. With its track record ...
Breaking Medicine News(10 mins):Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2
... 28 Dr. Eaton E.,Lattman, currently Dean of Research ... and Sciences at Johns Hopkins University (JHU), has,been appointed ... Research Institute. Lattman will assume the,position on July 1, ... has degrees from Harvard and JHU and at JHU ...
... medications longer, study finds , , FRIDAY, March 28 (HealthDay ... than the older drug haloperidol in treating a first ... it appears that more patients prefer the newer drugs ... haloperidol, the study authors said. , "When we compared ...
... Raleigh County League of,Democratic Women will conduct a mock ... Clinton and Barack Obama., "We,re not expecting the ... each one will be represented by two local,volunteers supporting ... be held at 6 p.m. Tuesday at the Raleigh ...
... using whole body 16 multi-detector CT (MDCT); theres no need ... recent study conducted by researchers at the University of Maryland ... in Baltimore, MD. The study showed that whole body MDCT ... In the past, blunt trauma patients would undergo whole-body MDCT ...
... from Boston University School of Medicine (BUSM) and ... found that decreased sexual satisfaction in postmenopausal women, ... study appears in the April 2008 issue of ... dysfunction is a common condition and has been ...
... to try technology like sensors,to detect falls and ... perception, and technical issues remain challenges, WASHINGTON, ... so they can age safely in their home. ... the challenges of caregiving.,Concerns such as cost to ...
Cached Medicine News:Health News:Hauptman-Woodward Appoints Dr. Eaton Lattman CEO and Executive Director 2Health News:Hauptman-Woodward Appoints Dr. Eaton Lattman CEO and Executive Director 3Health News:New Drugs No Better Than Older Ones for Schizophrenia 2Health News:New Drugs No Better Than Older Ones for Schizophrenia 3Health News:Whole body MDCT just as 'good' as neck MDCT angiography in diagnosing head and neck injuries 2Health News:Decreased sexual satisfaction is not associated with cardiovascular disease in postmenopausal women 2Health News:Older People Want to Use Technology to Help Them Remain at Home 2Health News:Older People Want to Use Technology to Help Them Remain at Home 3Health News:Older People Want to Use Technology to Help Them Remain at Home 4
Indications For Usage: , When patient's head is in an extended or flexed position When patient will be turned over. , Long-term cases where maintenance of an airway is critical. , Neurosurgical pr...
Indications For Usage: , Airway management during surgical procedures , Long-term ventilatory management ...
... The Thermal Angel® is an in-line, ... and IV fluid warming device, capable of ... Thermal Angel® can be used to help ... TA-200 will strive to achieve 38°C (100.4°F) ...
... is the only effective solution for ... surgical irrigation, especially urologic procedures. Patients ... of length of procedure or irrigant ... performance and is easy to set ...
Medicine Products: